{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:39:56Z","timestamp":1786991996423,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403284"],"award-info":[{"award-number":["82403284"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974478"],"award-info":[{"award-number":["81974478"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173009"],"award-info":[{"award-number":["82173009"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jdermsci.2025.06.003","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T11:44:02Z","timestamp":1750851842000},"page":"112-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Eupatilin attenuates vemurafenib resistance through inhibition of ABCB1 in melanoma"],"prefix":"10.1016","volume":"119","author":[{"given":"Daishi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchen","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangtong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jdermsci.2025.06.003_bib1","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jama.2022.24888","article-title":"What is melanoma?","volume":"329","author":"Wang","year":"2023","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.jdermsci.2025.06.003_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40257-018-0373-6","article-title":"Unusual clinical presentations of malignant melanoma: a review of clinical and histologic features with special emphasis on dermatoscopic findings","volume":"19","author":"Cabrera","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"issue":"26","key":"10.1016\/j.jdermsci.2025.06.003_bib3","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.jdermsci.2025.06.003_bib4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.jdermsci.2025.06.003_bib5","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.jdermsci.2025.06.003_bib6","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1158\/0008-5472.CAN-15-2137","article-title":"HSP70 inhibition limits FAK-Dependent invasion and enhances the response to melanoma treatment with BRAF inhibitors","volume":"76","author":"Budina-Kolomets","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.jdermsci.2025.06.003_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109747","article-title":"CHMFL-BMX-078, a BMX inhibitor, overcomes the resistance of melanoma to vemurafenib via inhibiting AKT pathway","volume":"351","author":"Jiang","year":"2022","journal-title":"Chem. Biol. Interact."},{"issue":"22","key":"10.1016\/j.jdermsci.2025.06.003_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27227800","article-title":"Identification of dihydrolipoamide dehydrogenase as potential target of vemurafenib-resistant melanoma cells","volume":"27","author":"Tabolacci","year":"2022","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"1","key":"10.1016\/j.jdermsci.2025.06.003_bib9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.jdermsci.2025.06.003_bib10","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s00109-021-02105-y","article-title":"ABCB1 in dermatology: roles in skin diseases and their treatment","volume":"99","author":"Weng","year":"2021","journal-title":"J. Mol. Med. (Berlin, Germany)"},{"issue":"1","key":"10.1016\/j.jdermsci.2025.06.003_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12943-022-01524-w","article-title":"CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1\/P-gp mediated multi-drug resistance (MDR) in cancer cells","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.jdermsci.2025.06.003_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/cgt.2016.17","article-title":"NF-\u03baB decoy polyplexes decrease P-glycoprotein-mediated multidrug resistance in colorectal cancer cells","volume":"23","author":"Abd Ellah","year":"2016","journal-title":"Cancer Gene Ther."},{"issue":"6","key":"10.1016\/j.jdermsci.2025.06.003_bib13","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1021\/mp200240a","article-title":"Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions","volume":"8","author":"Gillet","year":"2011","journal-title":"Mol. Pharm."},{"issue":"11","key":"10.1016\/j.jdermsci.2025.06.003_bib14","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1111\/1759-7714.13184","article-title":"ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy","volume":"10","author":"Zhong","year":"2019","journal-title":"Thorac. Cancer"},{"issue":"11","key":"10.1016\/j.jdermsci.2025.06.003_bib15","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1021\/mp3003144","article-title":"Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar","volume":"9","author":"Durmus","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jdermsci.2025.06.003_bib16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-pharmtox-010715-103111","article-title":"Toward a better understanding of the complexity of cancer drug resistance","volume":"56","author":"Gottesman","year":"2016","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"9","key":"10.1016\/j.jdermsci.2025.06.003_bib17","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/s42255-023-00861-4","article-title":"Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy","volume":"5","author":"Redondo-Mu\u00f1oz","year":"2023","journal-title":"Nat. Metab."},{"key":"10.1016\/j.jdermsci.2025.06.003_bib18","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1146\/annurev-biochem-011520-105201","article-title":"Structural and mechanistic principles of ABC transporters","volume":"89","author":"Thomas","year":"2020","journal-title":"Annu. Rev. Biochem."},{"issue":"12","key":"10.1016\/j.jdermsci.2025.06.003_bib19","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1021\/jm4004285","article-title":"QSAR modeling: where have you been? Where are you going to?","volume":"57","author":"Cherkasov","year":"2014","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.jdermsci.2025.06.003_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbab112","article-title":"Hyperbolic relational graph convolution networks plus: a simple but highly efficient QSAR-modeling method","volume":"22","author":"Wu","year":"2021","journal-title":"Brief. Bioinforma."},{"issue":"1","key":"10.1016\/j.jdermsci.2025.06.003_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbab365","article-title":"Using molecular embeddings in QSAR modeling: does it make a difference?","volume":"23","author":"Sabando","year":"2022","journal-title":"Brief. Bioinforma."},{"issue":"W1","key":"10.1016\/j.jdermsci.2025.06.003_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkab255","article-title":"ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties","volume":"49","author":"Xiong","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.jdermsci.2025.06.003_bib23","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/tox.23450","article-title":"Curcumin suppresses cell proliferation and triggers apoptosis in vemurafenib-resistant melanoma cells by downregulating the EGFR signaling pathway","volume":"37","author":"Chiu","year":"2022","journal-title":"Environ. Toxicol."},{"issue":"6502","key":"10.1016\/j.jdermsci.2025.06.003_bib24","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1126\/science.aaz6213","article-title":"Cell growth dilutes the cell cycle inhibitor Rb to trigger cell division","volume":"369","author":"Zatulovskiy","year":"2020","journal-title":"Science (New York NY)"},{"issue":"1","key":"10.1016\/j.jdermsci.2025.06.003_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-020-00572-6","article-title":"Mechanisms of resistance to BRAF-targeted melanoma therapies","volume":"22","author":"Dulgar","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"issue":"6","key":"10.1016\/j.jdermsci.2025.06.003_bib26","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ejca.2012.11.019","article-title":"Resistance to BRAF-targeted therapy in melanoma","volume":"49","author":"Sullivan","year":"2013","journal-title":"Eur. J. Cancer (Oxford England 1990)"},{"issue":"9","key":"10.1016\/j.jdermsci.2025.06.003_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185088","article-title":"Activation of phosphatidylinositol 3-kinase\/AKT\/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells","volume":"12","author":"Dong","year":"2017","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.jdermsci.2025.06.003_bib28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.biopha.2013.10.003","article-title":"Tamoxifen reduces P-gp-mediated multidrug resistance via inhibiting the PI3K\/Akt signaling pathway in ER-negative human gastric cancer cells","volume":"68","author":"Mao","year":"2014","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.jdermsci.2025.06.003_bib29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.imbio.2014.10.015","article-title":"Decreased expression of nucleophosmin\/B23 increases drug sensitivity of adriamycin-resistant Molt-4 leukemia cells through mdr-1 regulation and Akt\/mTOR signaling","volume":"220","author":"Wang","year":"2015","journal-title":"Immunobiology"},{"key":"10.1016\/j.jdermsci.2025.06.003_bib30","article-title":"DHW-221, a dual PI3K\/mTOR inhibitor, overcomes multidrug resistance by targeting P-glycoprotein (P-gp\/ABCB1) and Akt-mediated FOXO3a nuclear translocation in non-small cell lung cancer","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.jdermsci.2025.06.003_bib31","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.3892\/or.2016.4730","article-title":"Osthole shows the potential to overcome P-glycoprotein\u2011mediated multidrug resistance in human myelogenous leukemia K562\/ADM cells by inhibiting the PI3K\/Akt signaling pathway","volume":"35","author":"Wang","year":"2016","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.jdermsci.2025.06.003_bib32","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.jdermsci.2025.06.003_bib33","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s10495-016-1233-6","article-title":"Eupatilin induces Sestrin2-dependent autophagy to prevent oxidative stress","volume":"21","author":"Jegal","year":"2016","journal-title":"Apoptosis"},{"issue":"6","key":"10.1016\/j.jdermsci.2025.06.003_bib34","first-page":"2942","article-title":"Eupatilin inhibits the proliferation of human esophageal cancer TE1 cells by targeting the Akt\u2011GSK3\u03b2 and MAPK\/ERK signaling cascades","volume":"39","author":"Wang","year":"2018","journal-title":"Oncol. Rep."},{"issue":"6","key":"10.1016\/j.jdermsci.2025.06.003_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061459","article-title":"Eupatilin promotes cell death by calcium influx through ER-mitochondria axis with SERPINB11 inhibition in epithelial ovarian cancer","volume":"12","author":"Lee","year":"2020","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.jdermsci.2025.06.003_bib36","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.fct.2011.04.019","article-title":"Eupatilin, a dietary flavonoid, induces G2\/M cell cycle arrest in human endometrial cancer cells","volume":"49","author":"Cho","year":"2011","journal-title":"Food Chem. Toxicol."},{"issue":"6","key":"10.1016\/j.jdermsci.2025.06.003_bib37","article-title":"Eupatilin impacts on the progression of colon cancer by mitochondria dysfunction and oxidative stress","volume":"10","author":"Lee","year":"2021","journal-title":"Antioxidants (Basel, Switzerland)"},{"issue":"2","key":"10.1016\/j.jdermsci.2025.06.003_bib38","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3892\/mmr.2015.4671","article-title":"Anticancer effect of eupatilin on glioma cells through inhibition of the Notch-1 signaling pathway","volume":"13","author":"Wang","year":"2016","journal-title":"Mol. Med. Rep."},{"issue":"3","key":"10.1016\/j.jdermsci.2025.06.003_bib39","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1021\/np068054v","article-title":"Natural products as sources of new drugs over the last 25 years","volume":"70","author":"Newman","year":"2007","journal-title":"J. Nat. Prod."}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181125001252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181125001252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:02:20Z","timestamp":1757617340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181125001252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0923181125001252"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2025.06.003","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eupatilin attenuates vemurafenib resistance through inhibition of ABCB1 in melanoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2025.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}